Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 0421 • ACR Convergence 2020
Polymyalgia Rheumatica Is Associated with Later Menopause: An Observational Study
Sarah Dyball¹, Christopher Saleh² and Marwan Bukhari¹, ¹Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom, ²Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Manchester, United Kingdom
Background/Purpose: Oestrogen exposure leads to an increase in peak bone mass whereas menopause is associated with rapid bone loss. Numerous studies have linked rheumatoid arthritis…
Abstract Number: 0422 • ACR Convergence 2020
Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica
Sebastian Sattui¹, Deanna Jannat-Khah², Lindsay Lally¹, Sarah Lieber¹, Lisa Mandl¹ and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York City, NY, ³Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY
Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors. Frailty and pre-frailty have been reported in 10% and 44%of community dwelling elderly,…
Abstract Number: 0510 • ACR Convergence 2020
Expression and Functional Activity of the Angiotensin II System in Temporal Artery Lesions from Patients with Giant Cell Arteritis
Marco A. Alba¹, Ester Planas-Rigol², Marc Corbera-Bellalta², Nekane Terrades-García³, Ana García-Martínez³, Sergio Prieto-González¹, Roser Alba-Rovira³, Georgina Espígol-Frigolé¹, Javier Marco-Hernández¹, Jose Hernández-Rodríguez¹, Josep M Grau⁴ and Maria C. Cid¹, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, ⁴Department of Internal Medicine, Hospital Clínic and Fundació Cellex, University of Barcelona, Barcelona, Spain., Barcelona
Background/Purpose: Giant cell arteritis (GCA) is a large and medium size-vessel granulomatous vasculitis that predominantly affects the aorta and its major branches. The renin-angiotensin-aldosterone system…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].